SOLENO THERAPEUT. DL-001 (6XC) - Total Liabilities
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has total liabilities worth €113.72 Million EUR (≈ $132.94 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SOLENO THERAPEUT. DL-001 net asset momentum to track the company's year-over-year net asset growth rate.
SOLENO THERAPEUT. DL-001 - Total Liabilities Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's total liabilities have evolved over time, based on quarterly financial data. See SOLENO THERAPEUT. DL-001 free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
SOLENO THERAPEUT. DL-001 Competitors by Total Liabilities
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Affle (India) Limited
NSE:AFFLE
|
India | Rs6.58 Billion |
|
BRP Inc.
NASDAQ:DOO
|
USA | $6.04 Billion |
|
Enerflex Ltd.
TO:EFX
|
Canada | CA$2.37 Billion |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
Germany | €3.31 Billion |
|
Angang Steel Co Ltd Class A
SHE:000898
|
China | CN¥50.70 Billion |
|
Saigon Beer Alcohol Beverage Corp
VN:SAB
|
Vietnam | ₫10.32 Trillion |
|
Changzhou Fusion New Material Co. Ltd. A
SHG:688503
|
China | CN¥4.71 Billion |
|
Pharma Reaserch Prod Co Ltd
KQ:214450
|
Korea | ₩320.01 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SOLENO THERAPEUT. DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SOLENO THERAPEUT. DL-001 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SOLENO THERAPEUT. DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual total liabilities of SOLENO THERAPEUT. DL-001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €113.72 Million ≈ $132.94 Million |
+32.44% |
| 2024-12-31 | €85.86 Million ≈ $100.38 Million |
+270.34% |
| 2023-12-31 | €23.18 Million ≈ $27.10 Million |
+43.56% |
| 2022-12-31 | €16.15 Million ≈ $18.88 Million |
-9.07% |
| 2021-12-31 | €17.76 Million ≈ $20.76 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more